Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Appointed director

BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/02/2020 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of BioSpecifics Technologies Corp",
"Amended and Restated By-laws of BioSpecifics Technologies Corp",
"BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals WILMINGTON, DE - December 2, 2020 - BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America, today announced the successful completion of its acquisition by Endo International plc for approximately $658.2 million in equity value. Endo's all-cash tender offer to acquire all of the issued and outstanding shares of BioSpecifics' common stock at a purchase price of $88.50 per share expired one minute after 11:59 p.m., New York time, on December 1, 2020. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, reported that approximately 6..."
11/09/2020 8-K Quarterly results
Docs: "BioSpecifics Reports Third Quarter 2020 Financial and Operating Results"
10/19/2020 8-K Quarterly results
09/14/2020 8-K Quarterly results
08/31/2020 8-K Quarterly results
08/11/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
07/20/2020 8-K Quarterly results
07/14/2020 8-K Quarterly results
06/15/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BIOSPECIFICS TECHNOLOGIES CORP."
06/12/2020 8-K Investor presentation
Docs: "Presentation materials to be used by officers and other representatives of the Company"
06/08/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/11/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
04/10/2020 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Certificate of Designation of Series C Junior Participating Preferred Stock of BioSpecifics Technologies Corp",
"Rights Agreement, by and between BioSpecifics Technologies Corp. and Worldwide Stock Transfer, LLC, as rights agent",
"Stern Investor Relations, Inc."
04/09/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "BioSpecifics Appoints Joseph Truitt as Interim Chief Executive Officer WILIMINGTON, DE - April 9, 2020 - BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer. He will also serve on the Company's Board of Directors. Mr. Truitt succeeds J. Kevin Buchi, who served as CEO since October 2019, and has departed the company. “We are delighted to have Joe on board and believe he will play a major role in helping to shape the future of BioSpecifics. Joe is a highly experienced biopharma executive with a strong track record of clini...",
"BioSpecifics Appoints Mike Sherman and Corey Fishman to Board of Directors WILIMINGTON, DE - April 9, 2020 - BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX ® in North America, today announced that its Board of Directors appointed Mike Sherman and Corey Fishman to serve as Independent Directors, effective immediately. Mike Sherman and Corey Fishman will both join the Board's Audit Committee, with Mr. Sherman serving as an “audit committee financial expert.” Corey Fishman will also join the Intellectual Property Committee. “Mike and Corey both bring tremendous operational and functional insight, as well as industry and business acumen, to the..."
03/23/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Corporate Presentation Slides"
03/16/2020 8-K Quarterly results
01/13/2020 8-K Investor presentation
Docs: "Presentation materials to be used by officers and other representatives of the Company"
01/07/2020 8-K Termination of a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointmen...
11/21/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
10/23/2019 8-K Quarterly results
10/10/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer"
08/22/2019 8-K Investor presentation
Docs: "Presentation materials to be used by officers and other representatives of the Company"
08/09/2019 8-K Quarterly results
06/14/2019 8-K Submission of Matters to a Vote of Security Holders
05/23/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "BioSpecifics Technologies Corp. Announces Authorization of up to $4 Million Stock Repurchase Program"
05/10/2019 8-K Quarterly results
Docs: "BioSpecifics Technologies Corp. Reports First Quarter 2019 Financial and Operating Results - 14% year-over-year increase for BioSpecifics first quarter royalty revenues for XIAFLEX - - Phase 1 clinical trial of uterine fibroids completed - - BLA filing for XIAFLEX for treatment of cellulite expected in 2H19 -"
04/02/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/02/2019 8-K Quarterly results
Docs: "Press Release"
03/18/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman"
02/28/2019 8-K Quarterly results
02/21/2019 8-K Quarterly results
01/24/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter from Thomas L. Wegman"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy